Bank Of Nova Scotia Decreased Canadian Natl Ry Co (CNI) Stake By $45.21 Million; Redmile Group Raised Puma Biotechnology (PBYI) Position By $18.84 Million

May 18, 2017 - By Vivian Park

Redmile Group Llc increased Puma Biotechnology Inc (PBYI) stake by 94.8% reported in 2016Q4 SEC filing. Redmile Group Llc acquired 627,854 shares as Puma Biotechnology Inc (PBYI)’s stock 0.00%. The Redmile Group Llc holds 1.29 million shares with $39.61M value, up from 662,286 last quarter. Puma Biotechnology Inc now has $1.55B valuation. The stock rose 1.93% or $0.7 reaching $36.95 per share. About 328,294 shares traded. Puma Biotechnology Inc (NYSE:PBYI) has risen 6.00% since April 18, 2017 and is uptrending. It has by 0.00% the S&P500.

Bank Of Nova Scotia decreased Canadian Natl Ry Co (NYSE:CNI) stake by 17.91% reported in 2017Q1 SEC filing. Bank Of Nova Scotia sold 619,247 shares as Canadian Natl Ry Co (NYSE:CNI)’s stock 0.00%. The Bank Of Nova Scotia holds 2.84M shares with $209.30M value, down from 3.46 million last quarter. Canadian Natl Ry Co now has $55.45B valuation. The stock rose 0.69% or $0.5 reaching $73.4. About 369,258 shares traded. Canadian National Railway (USA) (NYSE:CNI) has risen 6.00% since April 18, 2017 and is uptrending. It has by 0.00% the S&P500.

Among 23 analysts covering Canadian National Railway (NYSE:CNI), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Canadian National Railway has $83 highest and $55 lowest target. $69.08’s average target is -5.89% below currents $73.4 stock price. Canadian National Railway had 48 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Nomura with “Neutral” on Tuesday, April 26. The firm has “Neutral” rating given on Friday, October 2 by Citigroup. The stock of Canadian National Railway (USA) (NYSE:CNI) has “Outperform” rating given on Friday, September 11 by National Bank Canada. The rating was initiated by Stephens on Tuesday, March 15 with “Equal-Weight”. The stock has “Overweight” rating by Morgan Stanley on Tuesday, February 23. Credit Suisse maintained it with “Neutral” rating and $58 target in Friday, February 19 report. Desjardins Securities upgraded Canadian National Railway (USA) (NYSE:CNI) on Wednesday, October 28 to “Buy” rating. Argus Research initiated Canadian National Railway (USA) (NYSE:CNI) on Tuesday, June 21 with “Buy” rating. The firm has “Outperform” rating given on Wednesday, January 4 by Raymond James. The stock has “Overweight” rating by First Analysis on Wednesday, January 27.

Bank Of Nova Scotia increased Bristol Myers Squibb Co (NYSE:BMY) stake by 341,702 shares to 934,926 valued at $50.84M in 2017Q1. It also upped Salesforce Com Inc (NYSE:CRM) stake by 457,466 shares and now owns 567,466 shares. Exxon Mobil Corp (NYSE:XOM) was raised too.

Canadian National Railway Company is engaged in the rail and related transportation business. The company has market cap of $55.45 billion. The Company’s network of approximately 20,000 route miles of track spans Canada and mid-America, connecting approximately three coasts, including the Atlantic, the Pacific and the Gulf of Mexico and serving the cities and ports of Vancouver, Prince Rupert , Montreal, Halifax, New Orleans, and Mobile (Alabama), and the metropolitan areas of Toronto, Edmonton, Winnipeg, Calgary, Chicago, Memphis, Detroit, Duluth (Minnesota)/Superior (Wisconsin), and Jackson (Mississippi), with connections to all points in North America. It has a 20.68 P/E ratio. The Company’s network and connections to all Class I railroads provide its clients access to the three North American Free Trade Agreement nations.

Investors sentiment decreased to 1.32 in 2016 Q4. Its down 0.17, from 1.49 in 2016Q3. It worsened, as 36 investors sold PBYI shares while 21 reduced holdings. 22 funds opened positions while 53 raised stakes. 34.24 million shares or 16.48% more from 29.40 million shares in 2016Q3 were reported. Everpoint Asset Mgmt owns 6,188 shares. Bb Biotech Ag invested in 0.28% or 241,991 shares. Rhumbline Advisers holds 0% of its portfolio in Puma Biotechnology Inc (NASDAQ:PBYI) for 32,033 shares. Perceptive Advsr Limited Liability Co owns 0.02% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 7,344 shares. Moreover, X Mngmt Ltd Liability has 0% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 146 shares. Geode Capital Mgmt Lc reported 198,181 shares. Wellington Group Limited Liability Partnership reported 2.37M shares. Putnam Ltd Liability Company holds 17,508 shares. Hbk LP accumulated 76,400 shares. Pub Employees Retirement Association Of Colorado has invested 0% in Puma Biotechnology Inc (NASDAQ:PBYI). American Century invested in 950,419 shares or 0.03% of the stock. Tourbillon Cap Ptnrs Ltd Partnership holds 448,471 shares. Teachers Retirement Sys Of The State Of Kentucky reported 61,874 shares or 0.02% of all its holdings. Blackrock Institutional Na owns 0% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 776,456 shares. Sivik Health Limited Liability accumulated 30,000 shares or 0.44% of the stock.

Since January 20, 2017, it had 0 insider buys, and 6 sales for $690,596 activity. 820 shares valued at $27,253 were sold by EYLER CHARLES R on Friday, January 20. Another trade for 3,008 shares valued at $95,755 was sold by CHARNAS ROBERT. Shares for $76,108 were sold by Lo Steven. AUERBACH ALAN H had sold 10,202 shares worth $339,064. $76,208 worth of Puma Biotechnology Inc (NASDAQ:PBYI) was sold by BRYCE RICHARD PAUL.

Redmile Group Llc decreased Incyte Corp (NASDAQ:INCY) stake by 145,651 shares to 451,987 valued at $45.32M in 2016Q4. It also reduced Amicus Therapeutics Inc (NASDAQ:FOLD) stake by 420,406 shares and now owns 12.33 million shares. Vca Inc (NASDAQ:WOOF) was reduced too.

Among 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Puma Biotechnology Inc had 14 analyst reports since August 27, 2015 according to SRatingsIntel. Citigroup initiated the stock with “Neutral” rating in Thursday, September 3 report. RBC Capital Markets downgraded it to “Sector Perform” rating and $36 target in Tuesday, March 29 report. The stock of Puma Biotechnology Inc (NASDAQ:PBYI) has “Buy” rating given on Monday, December 14 by Citigroup. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The rating was initiated by JP Morgan on Thursday, August 27 with “Overweight”. The stock of Puma Biotechnology Inc (NASDAQ:PBYI) has “Outperform” rating given on Thursday, September 22 by Credit Suisse. The company was maintained on Tuesday, March 29 by Citigroup. The rating was maintained by Credit Suisse on Tuesday, March 29 with “Outperform”. The stock of Puma Biotechnology Inc (NASDAQ:PBYI) earned “Outperform” rating by Credit Suisse on Wednesday, April 19. The stock of Puma Biotechnology Inc (NASDAQ:PBYI) earned “Buy” rating by UBS on Monday, April 11.